The 8 analysts offering 12-month price forecasts for Haemonetics Corp have a median target of 75.00, with a high estimate of 86.00 and a low estimate of 67.00. The median estimate represents a +47.89% increase from the last price of 50.72.
The current consensus among 8 polled investment analysts is to Buy stock in Haemonetics Corp. This rating has held steady since August, when it was unchanged from a Buy rating.Move your mouse over past months for detail
Earnings and Sales Forecasts
Earnings per Share $0.73
Reporting Date Feb 08
Earnings per Share
Move your mouse over a quarter or year to see how estimates have changed over time.